Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes.
about
Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin.Revolution of Alzheimer Precision Neurology Passageway of Systems Biology and Neurophysiology.The impact of transcranial magnetic stimulation on diagnostic confidence in patients with Alzheimer disease
P2860
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes.
@ast
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes.
@en
type
label
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes.
@ast
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes.
@en
prefLabel
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes.
@ast
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes.
@en
P2093
P2860
P50
P1476
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes
@en
P2093
Christopher C Rowe
Jillian J Kril
John R Hodges
Nicole Tom
Victor L Villemagne
P2860
P356
10.1016/J.DADM.2017.05.005
P577
2017-05-29T00:00:00Z